Abstract: Cardiovascular events such as myocardial infarction (MI) and stroke due to enhanced in flammatory atherosclerosis account for increased premature mortality in rheumatoid arthritis (RA). Ac cumulated evidence suggests that accelerated atherosclerosis and related cardiovascular comorbidities in RA are confounded not only by traditional risk factors (TRF) but also by a number of immune and inflammatory pathways. Since chronic inflammation and autoimmune disorders play a key role in athe rosclerosis and related cardiovascular complications in RA, effective suppression of systemic inflammation can be viewed as a strategy for cardiovascular therapy and prevention in this disease. This article overviews some mechanisms of action of methotrexate on TRF, clinical and subclinical manifestations of RA-induced atherosclerosis, and related cardiovascular morbidity and mortality.
INTRODUCTION
Several lines of evidence suggest that severity of rheuma toid inflammation, characterized by high number of inflamed joints, presence of extraparticular features, intensity of joints functional insufficiency, positivity for Rheumatoid Factor (RF) or Antibodies against Cyclic Citrullinated Proteins (ACCP), and elevated Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), and Interleukin-6 (IL-6), confound the development of cardiovascular complications (CVC) in RA [12] [13] [14] , Overly expressed proinflammatory cytokines and rela tively low levels of antiinflammatory cytokines keep rheu matoid autoimmune pathways persistently activated. Such a disbalance contributes to the endothelial dysfunction, vaso constriction, lipid peroxidation, hypercoagulation, and atherothrombosis, viewed by most experts as an extraarticular rheumatoid feature [15] [16] [17] [18] . Importantly, recent observa tions revealed that similar cellular infiltrates of monocytes, macrophages, and T-cells in atherosclerotic plaques and in flamed synovial membranes, coupled with the citmllination of fibrinogen and vimentin at both sites, add to the athero sclerotic burden in RA [19] .
Apparently, targeting rheumatoid inflammation and auto immune disorders by effective antiinflammatory agents seems a workable solution to the prevention of cardiovascu lar events in RA. Dampening rheumatoid inflammation by relatively safe means may reduce cardiovascular risk over a long-term. Cardiovascular effects of the widely-used and relatively safe disease-modifying antirheumatic drug (DMARD) methotrexate (MIX), known as a potent immu nosuppressive and antiinflammatory agent, are of particular interest [20, 21] . MTX is the first-line DMARD, which is effective for mono-and combined therapy of RA. It is often prescribed at the onset of the rheumatoid joint affection [22] .
Rheumatoid arthritis (RA) is a chronic inflammatory dis ease, which is characterized by enhanced cardiovascular morbidity and mortality [1] . One of the largest meta-analyses of cohort studies with pooled analysis of cardiovascular mor tality of 91,916 patients with RA demonstrated a 60% in crease in cardiovascular mortality in these patients, who were compared with the general population [2] . Such an in crease was largely attributed to the contribution of myocar dial infarction (MI) and stroke [3] , Cardiovascular risk in RA is comparable to that in type 2 diabetes [4] , viewed by some experts as a justification for cardiovascular prevention, tar geting common for RA and diabetes pathways [5] , Accelerated atherosclerosis in RA is driven not only by traditional risk factors (TRF) but also by common for these diseases immune and inflammatory mechanisms [6] , Prior to the onset of RA, TRF are accumulated and trigger systemic rheumatoid inflammation, eventually leading to clinical manifestations of atherosclerosis [7] [8] [9] , In fact, risk of unrec ognized MI in susceptible individuals prior to the develop ment of RA is 6 times greater than that in non-RA subjects [10] , Cardiovascular events due to rheumatoid inflammation tend to manifest a typically, with symptoms of angina being rarely reported. In patients with established RA, risk of un recognized MI and sudden death is doubled, compared to non-RA subjects [10] . The rapid increase of vascular events immediately after diagnosing RA suggests that rheumatoid immune disturbances start to play their critical role at that stage [11] , Early initiation of MTX monotherapy brings about protec tion for patients with RA, which is comparable to that of biologic agents [23] .
The aim of this article is to overview some of the impor tant mechanisms of cardiovascular effects of MTX and re lated implications for modifying risk factors and reducing cardiovascular and total mortality in RA.
receptors, triggered by MTX, may dilate coronary vessels and enhance blood flow in the myocardium.
It is now well known that MTX improves (reverses) cho lesterol (C) transport in patients with RA. Such an effect is mediated by adenosine, interacting with its receptors on macrophages and thereby activating enzymes, which are engaged in the metabolism and reverse transport of C from the vessel wall to the liver [39] . The increased expression of the 27-hydrolase gene leads to the transformation of C to more soluble 27-OH-cholesterol, whereas the increased ex pression of ATP-binding cassette transporter -Al (ABCA1) contributes to C transport from endothelial cells to HDL par ticles [40] . In fact, ABCA1 and 27-hydroxylase, antiathero genic proteins, stimulate the efflux of C. The inhibition of ABCA1 disrupts C and phospholipids elimination from cells, thus leading to the formation of their complexes with apoAl, which, in turn, reduces the formation of HDL particles.
Adenosine reduces die number of foam cells in the vessel wall in in-vitro conditions. Using a cell culture (human THP-1 monocytes/macrophages), it was shown that the activation of adenosine receptor A2a by MTX reverses transport of C and reduces formation of foam cells [35] , suggesting that the antiatherogenic effect of MTX is not limited to its direct an tiinflammatory action.
Notably, there is evidence that MTX promotes the inter action of insulin with its receptor, enhancing glucose influx into the cells [41] , which may have implications for over coming insulin resistance in RA. Plausible mechanisms of the improved glucose metabolism may also include direct stimulatory effect of adenosine on the glucose influx [42] .
To sum up, mechanisms of MTX action in RA are com plex. The main antiinflammatory effects and related cardio vascular protection in the course of MTX therapy may be associated with the activation of adenosine receptors, modu lation of pro-and antiinflammatory cytokines, and regulation of lipids and glucose metabolism.
MECHANISMS OF ACTION OF METHOTREXATE
MTX is an antimetabolite, or a substance chemically similar to its natural metabolite with which the drug petes in the process of DNA synthesis and cell reparation. The principal mechanism of action of MTX lies with its antifolate activity [24] . The drug exerts a cytotoxic effect due to the inhibition of dihydrofolatereductase (DHFR) and related decrease of intracellular levels of tetrahydrofolate, a carbon canner in the DNA synthesis. The inhibition of DHFR disrupts DNA synthesis, which underlies antiproliferative pathways in a range of clinical conditions, including MTX overdose [25, 26] .
Several mechanisms of low-dose MTX therapy have been explored, with the formation of an endogenous antiin flammatory mediator adenosine being considered the main driver of the efficiency in inflammatory disorders [27] . Adenosine-dependent actions of MTX inhibit the prolifera tion of endothelial cells and synovial fibroblasts, adhesion of white blood cells to the endothelium, and their migration to the inflamed tissues through capillaries and venules.
MTX dampens systemic inflammation in RA by modu lating synthesis of proinflammatory and immunoregulatory cytokines that may decrease the risk of atherothrombotic events [28] . On one hand, MTX suppresses the synthesis of interleukin (IL)-l, IL-6,1L-8, leukotrienes, and tumor necro sis factor (TNF)-a [29] [30] [31] , on the other, it increases produc tion of antiinflammatory cytokines, such as 1L-4 and IL-1Q [32, 33] . Th2-related cytokines IL-4 and IL-10, which are produced in response to MTX, inhibit the expression of Th 1 -related cytokines 1L-2 and interferon (INF)-y, bringing about an immunomodulatory effect.
MTX-induced immunomodulatory effect translates into vascular effects, retarding the course of athero thrombosis. The beneficial effects of MTX on the vessel wall in RA were reported not only due to the long-term therapy, but also in response to a single dose of MTX, which dropped levels of acute-phase proteins, inhibited neutrophils' chemotaxis, re duced reactive oxygen radicals, and lowered adhesion of leukocytes to the endothelium [34] .
A bulk of evidence also suggests that there may be sev eral indirect effec ts of MTX therapy on the course of atherogenesis and its complications in RA. In fact, it is hypothe sized that the enhanced production of adenosine, induced by G-proteins and adenylate cyclase, and T-cell activation drive most vascular effects of MTX [35, 36] . Large amounts of adenylate cyclase are found in basal ganglia, vessel wall, and platelets. A2a and A] receptors of endogenous adenosine play an important role in the regulation of coronary blood flow, oxygen consumption by the myocardium, and metabo lism of brain cells [37, 38] . The activation of A2a and A\
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METHOTREXATE THERAPY REDUCES CARDIO VASCULAR MORBIDITY AND MORTALITY
The reduced mortality rates in patients with chronic in flammatory arthritis, who are treated with MTX, are largely attributable to the antiinflammatory effects [43, 44] . In a landmark US-based cohort study of 5,626 patients with RA, followed up for 25 years, MTX therapy was associated with a 70% decline in total mortality (adjusted Hazard Ratio [HR] 0.3, 95% Confidence Interval [Cl] 0.09-1.03) [43] . In an other US-based study of 1,015 male patients with RA esti mated mortality rates were twice as high as those in the gen eral population and were independently associated with higher ESR and RF concentrations, increased DAS28, and prednisone use, among other covariates [44] , MTX therapy in that study was associated with a 37% decline in total mor tality (HR 0.63, 95% Cl 0.42-0.96) [44] , Several studies have specifically analyzed the effects of MTX therapy on cardiovascular risk, comorbidities, and mortality in RA. Some of these studies are presented in Ta ble 1. These are mostly U S-based retrospective analyses of large cohorts. Not all of these studies prove comprehensive cardiovascular protection on MTX therapy. Adjusted RR of CHF for current use of any DMARD, compared to no current use, was 0.7, 95% Cl 0.6-0.9; for MTX 0.8, 0.6 1.0; forrofecoxib 1.3, 1.0-3.1.
Incidence of hospitalizations for CHF 41885 patients (average age 51 years). During followup, 520 hospitalizations for CHF oc curred.
Case-control study Bernatsky S, et al. [52] HR for CHF development on MTX, compared to nonusers of MTX, 0.5, 95%CI 0.3-0.9
Incidence of CHF 795 patients (mean age 55 years), of whom 92 developed CHF during followup (mean 9. A landmark study of 1,240 patients with RA, followed up for 6 years at the Wichita Arthritis Center (US), demon strated a 70% decrease in the risk of cardiovascular mortality due to the exposure to various doses of MTX (HR 0.3, 95%CI 0.2-0.7, PO.OOl) [45J. In the same study, MTX did not have a significant effect on noncardiovascular mortality (HR 0.6, 95%CI 0.2-1.2). Also, in a case-control study of 613 patients with RA, MTX alone or in combination with other DMARDs (sulfasalazine and/or hydroxychloroquine) demonstrated a significant reduction of the risk of athero sclerotic vascular morbidity [46] , though the number of car diovascular events in that study was relatively low (72). In a much larger cohort of 16,752 patients, who were followed up for 4 years, the exposure to MTX decreased the risk of both atherosclerotic and nonatherosclerotic vascular manifesta tions (HR 0.65, 95% Cl 0.59-0.72) [47] ,
The notorious multicenter QUEST-RA study (Question naires in STandard Monitoring of Patients with Rheumatoid Arthritis Program) proved that prolonged MTX therapy was associated with a 15% decrease in the risk of all cardiovascu lar disorders and an 18% decrease in the risk of MI, irrespec tive of the prevalence of cardiovascular risk factors, RA ac tivity, and patients' functional status [48] , Similar trends in the risk reduction were apparent for leflunomide, sulfasa lazine, glucocorticoids, and biologic agents. Cases of fatal Mis were not analyzed in the QUEST-RA study.
A dose-dependent effect of MTX on CVD was analyzed in a cohort of 6,707 patients with RA (90% males) by Prodanovich S, et al [49] . Overall, a 17% decrease in the risk of cardiovascular disorders was noted due to MTX therapy (Relative Risk [RR] 0.83). Low-dose MTX therapy (<1.5 mg/week) was associated with decreased risk of ail cardio vascular diseases (RR-0.65, 95%CI 0.52-0.8) while high dose therapy (>30 mg/week) did not have such effect (RR=1.0; 95%CI 0.83-1.22). The absence of the effect might be due to the high intensity of rheumatoid inflammation, requiring high doses of MTX.
An analysis of the CORRONA (Consortium of Rheuma tology Researchers Of North America RA) registry also did not demonstrate any effect of MTX on a composite cardio vascular risk reduction (HR 0.94, . Therapy with TNF antagonists in the CORRONA study proved to significantly reduce the composite cardiovascular risk (HR 0.39, 95% Cl 0.19 to 0.82), though there were limi tations owing to the small number of cardiovascular events (88 for a cohort of 10,156 subjects) over a relatively short followup (23 months). A much larger North American cohort study (107,908 patients) did not find any cardiovascular benefit of biologic therapy and simply a borderline effect of MTX on reduction of MI risk (Rate Ratio 0.81, 95%CI 0.60 1.08) [51], Likewise, MTX was found to have a borderline effect on the reduction of the risk of hospitalizations due to heart failure (0.8, 95%CI 0.6-1.0) [52] . Finally, a study of 795 patients, of whom 92 developed heart failure during the followup, reported a 50% heart failure risk reduction for those on MTX, compared to nonusers of MTX (0.5, 95%CI 0.3-0.9) [53], To sum up, MTX therapy brings about cardiovascular protection in RA by controlling systemic inflammation and reducing related risk of atherosclerotic vascular events [54, 55] , Notably, a pooled analysis of 8 prospective and 2 retro spective cohort studies on MTX with a total of 66,334 sub jects with inflammatory arthritis, who developed 6,235 car diovascular events, demonstrated a 21% cardiovascular dis ease and an 18% MI risk reduction [55] . Such a significant cardiovascular risk reduction persisted after adjustment for underlying disease severity and concomitant use of other drugs.
METHOTREXATE THERAPY AND CARDIOVAS CULAR RISK FACTORS IN RA
Several cross-sectional and longitudinal studies have evaluated the influence of MTX on separate cardiovascular risk factors and markers, which may confound the drug's effects on cardiovascular morbidity and mortality (Table 2 ) [56] [57] [58] [59] [60] . Limitations of these studies are related to small number of patients, short followup periods, and absence of proper controls for concomitant use of multiple antiinflam matory drugs, and primarily glucocorticoids.
MTX therapy dampens systemic inflammation and re duces levels of inflammatory markers, which may alter lipid profiles. A pilot 3-month study of MTX therapy and reduced saturated fatty acids diet in RA demonstrated a significant decrease of CRP without meaningful alterations of lipids [56] , A one-year study of 39 patients with RA on MTX ther apy revealed improvements in the course of arthritis in 27 patients with a significant elevation of HDL-C (PO.OOl) and nonsignificant decrease of the atherogenic index (LDL-C/HDL-C ratio) [57] . In another cohort of 58 patients with early RA one-year stable MTX therapy at 15.5 mg/week along with low-dose prednisone significantly decreased atherogenic index that correlated with decreased ESR and CRP [58] .
Decreased triglyceride and increased HDL-C were also noted in the UK-based Dudley cohort of 387 patients, which was due to the regular long-term MTX therapy [59] . Logistic regression analysis proved that MTX use is associated with low risk of the metabolic syndrome in RA in the same cohort (adjusted Odds Ratio 0.517, 95%CI 0.33-0.81, P-0.004) [59] that may be due to lipid-regulating but not to antihyperten sive effects of MTX therapy [60], Altogether, preliminary longitudinal and retrospective cohort studies suggest that MTX suppresses systemic in flammation and regulates cholesterol transport, thereby de creasing atherogenic index. Specifically designed and prop erly controlled long-term prospective studies are warranted to confirm these results.
An important issue arises as to whether MTX therapy in fluences atherosclerotic risk markers in RA. A few prelimi nary studies examining intimal-medial thickness and athero sclerotic plaques of the common carotid and femoral arteries in small cohorts, revealed no changes between those treated and nontreated with MTX over 3-24 months [61-63] . Biol ogies seem to exert a more pronounced effect on the arterial intima [63] , though large prospective studies are still pending to evaluate vascular benefits of MTX and its comparators.
Finally, there are concerns that cardioprotective benefits of MTX therapy may be diminished by the inhibition of ho mocysteine-methionine pathway and the resultant hyperho- Revisited Current Medicinal Chemistry, 2015 , Voi. 22, No, 16 1907 Tabic 2. Studies of the effect of methotrexate on lipid profiles and hypertension in patients with RA. induced gastrointestinal adverse effects and hepatic dysfunc tion [77] . That systematic review also proved the crucial role of folic acid supplementation in avoiding MTX discontinua tion for any reason, though no data were presented on car diovascular risk. Further large prospective studies on the effect of folic acid supplementation on cardiovascular mor bidity and mortality in RA are still pending.
Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis
CONCLUSION RA is a chronic progressive inflammatory disorder with enhanced cardiovascular risk. Numerous (aiito)inimune and inflammatory pathways leading to atherothrombosis in RA have been explored. Proinflammatory cytokines, which are produced by macrophages/monocytes, neutrophils, platelets, and other immune cells, induce rheumatoid inflammation in the joints' synovium and vascular wall, subsequently damag ing the endothelium, altering cholesterol transport, and enhacing thrombogenicity [78] [79] [80] , Continuous suppression of the production of proinflammatory cytokines is therefore a strategy to tackle with the highly prevalent cardiovascular risk factors and comorbidities in RA. mocysteinemia, a modifiable cardiovascular risk factor [64 66] . Indeed, hyperhomocysteinemia is often reported in pa tients with RA on low-dose MTX therapy (5-25 mg/week) [67] , and particularly in male patients, subjects with ad vanced radiological damage [68] , and those exposed to com bined MTX and sulfasalazine therapy [69] . A recent IJSbased cohort study distinguished hyperhomocysteinemia as a factor independently tripling the risk of hypertension in RA [70] . Elevated homocysteine can damage endothelial cells, trigger LDL oxidation, contribute to the production of proin flammatory HDL and asymmetric dimethylarginine, and thereby enhance atherothrombosis [71] [72] [73] .
Currently available evidence, derived from small pro spective cohort studies, suggests that continuous folic acid supplementation overcomes MTX-induced hyperhomocys teinemia that may contribute to the overall cardiovascular protection in RA [74] [75] [76] . And a recent Cochrane systematic review of 6 trials with 624 patients supported a protective effect of supplementation with low-dose of folic acid (below 7 mg/week), which allows to reduce the incidence of MTX-MTX is the first-line DMARD, which is widely used for mono-and combined therapy of RA. With earlier and unin terrupted use of MTX, it is possible to effectively control the immune inflammation in the joints and vascular walls, thereby improving cardiovascular and total mortality in RA. Several systematic reviews and meta-analyses of observa tional cohorts prove that despite the availability of numerous synthetic DMARDs, potently suppressing inflammatory pathways in RA, MTX with its moderate antiinflammatory properties retains its position as a relatively safe drug with beneficial thrombogenic and atherogenic profiles [54, 55, 81, 82] , It is plausible that MTX therapy may have better out comes with folic acid supplementation. Large prospective studies are warranted to comparatively assess cardiovascular implications of MTX, biologies, and other antiinflammatory agents. One such prospective, one-year cardiovascular imag ing study, which is called Coronary Artery Disease Evalua tion in Rheumatoid Arthritis (CADERA), is now underway to examine 120 patients with early, treatment naïve RA, ran domized to MTX and combinations of MTX with synthetic DMARDs [83],
In the meanwhile, low-dose MTX is actively promoted as a safe and potentially effective means for secondaiy preven tion of cardiovascular events in high-risk non-RA cohorts 
